<?xml version="1.0" encoding="UTF-8"?>
<p id="p0215">A new governance model was called for to accelerate global health innovation and impact, where private and public partners are aligned in a manner that proactively defines roles and responsibilities, specifies key data needed for future policy decisions, secures procurement and implementation, and shares risks in a reasonable manner. Particularly to improve the availability in poorer regions, medicines must be governed better because it is not possible at the same time to maximize profit in medicines and have affordable medicines for all.</p>
